China-based clinical stage biopharmaceutical company Zhejiang Doer Biologics Co., Ltd. (Doer Bio) announced on Sunday that it has completed enrolment in the phase two clinical study of DR10624 intended for the treatment of severe hypertriglyceridemia (SHTG).

DR10624 is the first-in-class, tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), and Glucagon-like peptide-1 receptor (GLP-1R). The DR10624-201 study is a randomised, placebo-controlled, double-blind study to evaluate the efficacy and safety of three dose levels of DR10624 in adult SHTG patients, who have mean fasting triglycerides of greater than or equal to 5.65 mmol/L (500 mg/dL) at screening. A total of 79 SHTG patients have been enrolled in the 12 weeks study.

Yongliang Fang, PhD, Doer Bio chief operating officer, said, 'We're excited to announce the successful completion of patient enrolment in the DR10624-201 study. There is growing awareness of the public health threat posed by SHTG. Patients with SHTG face an increased risk of developing acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD), conditions that elevate the risk of hospitalisation and death. The DR10624-201 study aims to determine the optimal dose for advancing DR10624 as a novel biologic treatment for patients suffering from SHTG. The topline data is expected in the third quarter of 2025.'